Home / Health / EU Approves Novo Nordisk's Oral Wegovy for Obesity
EU Approves Novo Nordisk's Oral Wegovy for Obesity
15 Jul
Summary
- Novo Nordisk's Wegovy pill received European Commission approval.
- This marks the first oral GLP-1 weight-loss treatment in the EU.
- The pill is for adults with obesity or who are overweight.
On Wednesday, July 15, 2026, the European Commission granted approval for Novo Nordisk's once-daily Wegovy pill. This landmark decision makes Wegovy the first oral GLP-1 treatment specifically cleared for weight management in adults across the European Union. The approval targets individuals who are obese or overweight, offering a new therapeutic option.
This development represents a significant step forward in the availability of weight-loss solutions within the EU. The oral formulation of Wegovy provides a convenient alternative for patients compared to injectable treatments.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
